Homozygous familial hypercholesterolemia: genes and variants
Explore variant evidence for Homozygous familial hypercholesterolemia across 3 analyzed proteins (LDLR, APOB, PCSK9). Linked ClinVar records include 29 pathogenic or likely pathogenic variants, 0 variants of uncertain significance and 2 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Homozygous familial hypercholesterolemia
LDLR: Low-density lipoprotein receptor
It removes ApoB-containing LDL particles from the circulation through receptor-mediated endocytosis, especially in hepatocytes. Loss-of-function variants are the most common cause of familial hypercholesterolemia and lead to lifelong LDL elevation and premature atherosclerotic disease.
26 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in LDLR have source records linked to Homozygous familial hypercholesterolemia. Association strength is not clinical gene validity.
APOB: Apolipoprotein B-100
It provides the structural backbone for triglyceride-rich lipoproteins and LDL, while ApoB-100 also mediates LDL-receptor binding and clearance. Pathogenic variants can cause familial hypobetalipoproteinemia or defective ApoB-related hypercholesterolemia depending on their effect on particle assembly and receptor binding.
2 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in APOB have source records linked to Homozygous familial hypercholesterolemia. Association strength is not clinical gene validity.
PCSK9: Proprotein convertase subtilisin/kexin type 9
By binding hepatic LDL receptors and promoting their lysosomal degradation, it reduces receptor recycling and raises circulating LDL cholesterol. Gain-of-function variants cause autosomal dominant hypercholesterolemia, whereas loss-of-function variants lower LDL cholesterol and cardiovascular risk.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PCSK9 have source records linked to Homozygous familial hypercholesterolemia. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Homozygous familial hypercholesterolemia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| LDLR C134R | 134 | LDL-receptor class A 3 | Pathogenic / likely pathogenic (★★) |
| LDLR C197Y | 197 | LDL-receptor class A 5 | Pathogenic / likely pathogenic (★★) |
| LDLR C134F | 134 | LDL-receptor class A 3 | Pathogenic / likely pathogenic (★★) |
| APOB R3527W | 3527 | Pathogenic / likely pathogenic (★★) | |
| LDLR C89Y | 89 | LDL-receptor class A 2 | Pathogenic / likely pathogenic (★★) |
| LDLR D168N | 168 | LDL-receptor class A 4 | Pathogenic / likely pathogenic (★★) |
| LDLR Q254P | 254 | LDL-receptor class A 6 | Pathogenic / likely pathogenic (★★) |
| LDLR C261F | 261 | LDL-receptor class A 6 | Pathogenic / likely pathogenic (★★) |
| LDLR C313Y | 313 | LDL-receptor class A 7 | Pathogenic / likely pathogenic (★★) |
| LDLR C340Y | 340 | EGF-like 1 | Pathogenic / likely pathogenic (★★) |
| LDLR D354G | 354 | EGF-like 2 | Pathogenic / likely pathogenic (★★) |
| LDLR R416Q | 416 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★) |
| LDLR R416W | 416 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★) |
| LDLR C677R | 677 | EGF-like 3 | Pathogenic / likely pathogenic (★★) |
| APOB R3527Q | 3527 | Pathogenic / likely pathogenic (★★) | |
| LDLR C197G | 197 | LDL-receptor class A 5 | Pathogenic / likely pathogenic (★★) |
| LDLR D227G | 227 | LDL-receptor class A 5 | Pathogenic / likely pathogenic (★★) |
| LDLR C340L | 340 | EGF-like 1 | Pathogenic / likely pathogenic (★★) |
| LDLR C148Y | 148 | LDL-receptor class A 4 | Pathogenic / likely pathogenic (★★) |
| LDLR E208K | 208 | LDL-receptor class A 5 | Pathogenic / likely pathogenic (★★) |
| LDLR H211Y | 211 | LDL-receptor class A 5 | Pathogenic / likely pathogenic (★★) |
| LDLR G546V | 546 | LDL-receptor class B 4 | Pathogenic / likely pathogenic (★★) |
| LDLR N564H | 564 | LDL-receptor class B 4 | Pathogenic / likely pathogenic (★★) |
| LDLR P685L | 685 | EGF-like 3 | Pathogenic / likely pathogenic (★★) |
| LDLR E140D | 140 | LDL-receptor class A 3 | Pathogenic / likely pathogenic (★★) |
| LDLR G545E | 545 | LDL-receptor class B 4 | Pathogenic / likely pathogenic (★★) |
| LDLR G565V | 565 | LDL-receptor class B 4 | Pathogenic / likely pathogenic (★★) |
| LDLR V797M | 797 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| PCSK9 E32K | 32 | Pathogenic / likely pathogenic (★★) |
Which prediction tools work for Homozygous familial hypercholesterolemia
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- REVEL: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 98 out of 100
- MetaSVM: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 96 out of 100
- AlphaMissense: 93 out of 100
- CADD: 93 out of 100
- PolyPhen-2: 91 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 88 out of 100
- phyloP: 87 out of 100
- SpliceAI: 56 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 45 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Familial hypercholesterolemia also has ClinVar records linked to LDLR variants; they fall mostly in different places as the Homozygous familial hypercholesterolemia variants (668 pathogenic / likely pathogenic).
- Dyslipidemia also has ClinVar records linked to LDLR variants; they fall mostly in different places as the Homozygous familial hypercholesterolemia variants (32 pathogenic / likely pathogenic).
- Familial hypobetalipoproteinemia also has ClinVar records linked to APOB variants; they fall mostly in different places as the Homozygous familial hypercholesterolemia variants (7 pathogenic / likely pathogenic).
- Familial hypercholesterolemia also has ClinVar records linked to APOB variants; they fall mostly in different places as the Homozygous familial hypercholesterolemia variants (3 pathogenic / likely pathogenic).
- Familial hypercholesterolemia also has ClinVar records linked to PCSK9 variants; they fall mostly in different places as the Homozygous familial hypercholesterolemia variants (8 pathogenic / likely pathogenic).
Diseases related to Homozygous familial hypercholesterolemia
- Familial hypercholesterolemia, also linked to APOB, LDLR and PCSK9
- Myocardial infarction, also linked to APOB, LDLR and PCSK9
- Heart disease, also linked to LDLR and PCSK9
- Dyslipidemia, also linked to LDLR
- Familial hypobetalipoproteinemia, also linked to APOB
Frequently asked questions
Which genes have records linked to Homozygous familial hypercholesterolemia?
This view contains 3 analyzed proteins: LDLR, APOB, PCSK9. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 29 pathogenic or likely pathogenic variants, 0 variants of uncertain significance and 2 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 31 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center